SHANGHAI, Jan. 27, 2014 /PRNewswire/ -- Sundia MediTech Group, a leading China-based CRO Service Company announced today that Dr. Ruiping Dong has been appointed as Sr. Advisor to the Board.
Prior to Sundia, Dr. Dong was a senior Vice President & Head of Emerging Markets R&D at Merck, responsible for overseeing Research & Development activities within Emerging Markets, building Emerging Markets Research & Development organization, and working with Commercial and manufacture divisions to lead overall Emerging markets strategy and execution. Prior to that, he spent more than 6 years with Bristol-Myers Squibb and 6 years with AstraZeneca respectively.
"I am honored to be appointed to work with the Sundia Board," said Dr. Ruiping Dong. "Sundia is one of the top leading CROs to provide drug discovery and development services worldwide. The company has demonstrated its strong growth with business, a well-designed model and most importantly a world-class management team. I will continue to leverage my knowledge and network on behalf of Sundia to further accelerate the growth."
"Dr. Dong has numerous year of experience in pharmaceutical industry and his join will certainly strengthen our business and operation," said Dr. Chen Chen, CEO of Sundia. "We are very pleased to welcome Dr. Dong to the Sundia Board."
Ms. Cathy Yen, Chairman of Sundia said: "Dr. Dong is a prominent leader who has significant management experience and a solid record of achievement. We look forward to his bringing more knowledge and insight into Sundia. I am very pleased to welcome Dr. Dong as a Sr. Advisor to the Board. I am sure that his sophisticated management experience and extensive international network will benefit our company and shareholders.
Founded by a group of veterans from the US pharmaceutical and biotech industry in 2004, Sundia MediTech Company Ltd. is now a leading Chinese CRO company providing quality, efficient, and cost-effective services in every stage of drug discovery and/ or pharmaceutical development, particularly in chemistry synthesis and pre-clinical studies. By August 2013, three INDs were approval by CFDA and one IND approval by US FDA through pre-clinical study collaborations with Sundia. For more information, please check http://www.sundia.com